Zimberelimab (AB122)

Note: Zimberelimab is approved in China, but does not appear to have a brand name at this time.

Mechanism of action

PD-1 inhibitor

Diseases for which it is used

• Hodgkin lymphoma

History of changes in NMPA indication

• 2021-08-30: Approved for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).

Also known as

• Code names: AB122, GLS-010